RETRACTED ARTICLE: A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptin in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level

Parsanezhad, Mohammad Ebrahim; Alborzi, Saeed; Jahromi, Bahia Namavar

doi:10.1007/s00404-002-0437-x

Cited by 14 publications

(9 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kubota et al [15] stated a lesser ovulation rate of 57.3% and pregnancy rate of 27% of infertile females that have euprolactinemia used CC and bromocriptine. Parsanezhad et al [16] evaluated that the influence of addition bromocriptine to CC in PCOS euprolactinemic females that resist CC, no significant difference in gestational rate and ovulation in the study group. However, there is only a significant effect of bromocriptine in lowering PRL [16].…”

Section: Discussionmentioning

confidence: 99%

Improving pregnancy rate in infertile patients with polycystic ovarian syndrome receiving clomiphene citrate and cabergoline in euprolactinomic women in single cycle treatment

Witwit

2022

Ginekol Pol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Improving pregnancy rate in infertile patients with polycystic ovarian syndrome receiving clomiphene citrate and cabergoline in euprolactinomic women in single cycle treatment

Witwit

2022

Ginekol Pol

View full text Add to dashboard Cite

show abstract

“…In vitro experiments indicated a high PRL level conferred suppressive effects. Feltus et al (13) have shown PRL could activate the expression of 3b-hydroxysteroid dehydrogenase II, which is a terminal enzyme in the biosynthesis of P. Previous studies have showed oral bromocriptine could decrease the serum PRL level in healthy women, accompa nied by a marked decrease in the P level in the luteal phase (14). Additionally, corpus luteum insufficiency was also noted in the endometrial biopsy.…”

Section: Effects Of Transitory Hyperprolactinemia On the Pregnancy Inmentioning

confidence: 96%

Impact of Transitory Hyperprolactinemia on Clinical Outcome of In Vitro Fertilization and Embryo Transfer

Zhong¹,

Shen²,

Ying³

et al. 2012

Journal of Medical Biochemistry

View full text Add to dashboard Cite

Summary: This study aimed to evaluate the impact of serum prolactin concentration at the day of human chorio nic gonadotropin (HCG) administration on the clinical outcome of in vitro fertilization and embryo transfer (IVF-ET). A total of 184 patients receiving the IVF-ET/ICSI-ET from Octo ber 2005 to March 2008 were retrospectively analyzed. Sub jects were divided into four groups according to the serum prolactin concentration [<30 ng/mL (A), 30-60 ng/mL (B), 60-90 ng/mL (C), ≥90 ng/mL (D)] on the day of HCG administration during controlled ovarian stimulation (COS). In the Groups A, B, C and D, the implantation rate was 11.76%, 19.71%, 12.72% and 2.22%, respectively, and the pregnancy rate (PR) was 25.00%, 42.70%, 27.30% and 5.88%, respectively. The implantation rate and PR in the Group D were markedly lower than those in the remaining groups (P=0.011 and 0.009). During the COS, the serum prolactin concentration was dramatically elevated when compared with the base line level leading to transient hyperprolactinemia. In addition, the implantation rate and pregnancy rate were significantly markedly decreased when the serum prolactin concentration was remarkably increased (≥90 ng/mL). To improve the clinical pregnancy rate of IVF-ET, close monitoring and appropriate intervention are needed for patients with an abnormal prolactin level during the COS.Keywords: hyperprolactinemia, in vitro fertilization and embryo transfer, human chorionic gonadotropin, clinical pregnancy Kratak sadr`aj: Ova studija sprovedena je kako bi se procenio uticaj koncentracije prolaktina u serumu na dan administracije humanog horionskog gonadotropina (HCG) na klini~ki ishod in vitro oplodnje i transfera embriona (IVF-ET). Retrospektivna analiza je obuhvatila ukupno 184 pacijenta podvrgnuta IVF-ET/ICSI-ET izme|u oktobra 2005. i januara 2008. Ispitanici su podeljeni u ~etiri grupe na osnovu koncentracije prolaktina u serumu [<30 ng/mL (A), 30-60 ng/mL (B), 60-90 ng/mL (C), ≥90 ng/mL (D)] na dan administracije HCG tokom kontrolisane stimulacije jajnika (COS). U grupama A, B, C i D stopa implantacije bila je 11,76%, 19,71%, 12,72% i 2,22%, dok je stopa ostvarenih trudno}a (PR) bila 25,00%, 42,70%, 27,30% i 5,88%. Stopa im plantacije i PR u grupi D bile su upadljivo ni`e nego u ostalim grupama (P=0,011 i 0,009). Tokom COS, koncentra cija prolaktina u serumu bila je dramati~no povi{ena u pore|enju sa po~etnim nivoom, {to je dovelo do prolazne hiperprolaktinemije. Pored toga, stopa implantacije i stopa ostvarenih trudno}a bile su zna~ajno i upadljivo ni`e kada je koncentracija prolaktina u serumu bila izrazito povi{ena. Pa`ljivo pra}enje i odgovaraju}e intervencije potrebni su kako bi se pobolj{ala klini~ka stopa ostvarenih trudno}a u IVF-TE kod pacijenata sa abnormalnim nivoom prolaktina tokom kontrolisane stimulacije jajnika.Klju~ne re~i: hiperprolaktinemija, ve{ta~ka oplodnja i transfer embriona, humani horionski gonadotropin, klini~ka trudno}a List of abbreviations: PRL -prolactin, IVF-ET -in vitro fertilization and embryo transfer, COS -cont...

show abstract

“…In fact, bromocriptine administration has given no benefit in clomifene citrate-resistant PCOS patients with normal prolactin levels receiving 150 mg clomifene citrate (days 5-9) and bromocriptin continuously administrated at a dosage of 7.5 mg daily [97]. On the contrary, the use of cabergoline has been proved to improve ovarian response in hyperprolactinemic patients with PCOS candidates for treatment with gonadaotropins [98].…”

Section: Bromocriptinementioning

confidence: 97%

Management strategies for ovulation induction in women with polycystic ovary syndrome and known clomifene citrate resistance

Palomba

Falbo

Zullo

2009

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

RETRACTED ARTICLE: A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptin in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level

Cited by 14 publications

References 17 publications

Improving pregnancy rate in infertile patients with polycystic ovarian syndrome receiving clomiphene citrate and cabergoline in euprolactinomic women in single cycle treatment

Improving pregnancy rate in infertile patients with polycystic ovarian syndrome receiving clomiphene citrate and cabergoline in euprolactinomic women in single cycle treatment

Impact of Transitory Hyperprolactinemia on Clinical Outcome of In Vitro Fertilization and Embryo Transfer

Management strategies for ovulation induction in women with polycystic ovary syndrome and known clomifene citrate resistance

Contact Info

Product

Resources

About